Table 1 General information of the participants
|  | Participants (n = 131) |
|---|---|
Age, year | 60.15 ± 11.17 |
Male, n (%) | 62 (47.3) |
Body mass index, kg/m2 | 25.64 ± 3.52 |
Heart rate, beats/min | 71.87 ± 10.49 |
Systolic blood pressure, mmHg | 134.54 ± 16.72 |
Diastolic blood pressure, mmHg | 75.32 ± 10.55 |
Pulse pressure, mmHg | 58.62 ± 16.28 |
Homocysteine, μmol/L | 14.01 ± 8.27 |
Glucose, mmol/L | 5.54 ± 1.49 |
HbA1c, % | 6.16 ± 0.85 |
Serum creatinine, μmol/L | 66.59 ± 15.58 |
Uric acid, μmol/L | 334.27 ± 93.42 |
Total cholesterol, mmol/L | 4.19 ± 0.84 |
Triglyceride, mmol/L | 1.77 ± 1.00 |
High-density lipoprotein cholesterol, mmol/L | 1.33 ± 0.34 |
Low-density lipoprotein cholesterol, mmol/L | 2.39 ± 0.68 |
Ejection fraction, % | 65.69 ± 7.14 |
Flow-mediated dilatation, % | 7.311 ± 5.259 |
Hypertension | 68 (51.9) |
Diabetes mellitus | 30 (23.3) |
Smoking | 28 (21.4) |
Family history of premature cardiovascular disease | 27 (20.6) |
Antiplatelet therapy | 35 (26.7) |
β-blocker | 28 (21.4) |
Calcium antagonist | 35 (26.7) |
Angiotensin-converting-enzyme inhibitors / angiotensin II receptor blockers | 35 (26.7) |
Diuretics | 10 (7.6) |
Statins | 28 (21.4) |
Hypoglycemic agents | 22 (16.8) |